Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
Yokote. Koutaro K; Fukushima. Yasushi Y; Shingaki. Tomotaka T; Oura. Tomonori T; Ogawa. Wataru W
Key Findings
- Tirzepatide 10 mg and 15 mg caused 15‑25% body‑weight reductions after 72 weeks, far greater than placebo.
- Women and participants with BMI < 35 kg/m² tended to lose slightly more weight than men or those with BMI ≥ 35 kg/m².
- 86‑100% of tirzepatide users achieved ≥5% weight loss versus 18‑30% on placebo, with improvements in cardiometabolic markers and no major safety differences across subgroups.
Practical Outcomes
- For self‑experimenters, tirzepatide appears to be a potent weight‑loss tool that works across ages and sexes, but women and those with lower baseline BMI may see the biggest drops. Starting with the 10 mg dose and titrating up to 15 mg could fine‑tune results while keeping side‑effects low. Monitoring weight, BMI category, and cardiometabolic health can help personalize dosing for optimal outcomes.
Summary
In a Japanese obesity study, weekly tirzepatide injections (10 mg or 15 mg) led to big weight drops over 72 weeks, with women and people with a lower starting BMI losing a bit more. Almost everyone on tirzepatide lost at least 5% of their weight, while only a few on placebo did. Blood sugar, cholesterol, and other heart‑related numbers also improved, and side‑effects were similar across groups.
Abstract
This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. This was a prespecified subgroup analysis of the SURMOUNT-J trial. Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo. Key safety and efficacy outcomes at week 72 were analysed by baseline characteristics, including sex, age (<65, ≥65 years), and body mass index (BMI; <35 kg/m<sup>2</sup>, ≥35 kg/m<sup>2</sup>). Post hoc analyses were conducted to examine cardiometabolic parameters by subgroup. Overall, 225 participants were examined (tirzepatide 10 mg: n = 73; tirzepatide 15 mg: n = 77; placebo: n = 75). Weight reduction at week 72 was generally similar across subgroups. Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%) and in the BMI <35 kg/m<sup>2</sup> subgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/m<sup>2</sup> subgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo. Higher proportions of participants achieved ≥5% weight reduction following week 72 of tirzepatide (86%-100%) compared with placebo (18%-30%) across subgroups, and all subgroups showed improvements in cardiometabolic parameters with tirzepatide. Safety profiles did not substantially differ by subgroup. These results suggest that tailored interventions such as tirzepatide dosage adjustments may help optimise the treatment management of Japanese patients with obesity disease. ClinicalTrials.gov, NCT04844918.
Study Information
pubmed
2025
2025-11-25T00:00:00.000Z
10.1111/dom.70315
32